Biologic Medicines-Focused Comera Life Sciences Turns To SPAC For NASDAQ Debut

Comera Life Sciences Inc has agreed to go public through a merger with OTR Acquisition Corp OTRA, a blank-check company.

  • The combined company will have an initial equity value of about $258.4 million. The companies said it would provide about $107 million in gross cash proceeds.
  • All 12.6 million shares will be issued to Comera stockholders at an implied value of $10 per share. 
  • The transaction also includes a potential earn-out to Comera shareholders, including 3.15 million more shares.
  • The SPAC is led by investor and entrepreneur Nicholas J. Singer, who serves as chairman and CEO. 
  • After the transaction closes, Jeff Hackman, Comera’s CEO, will lead the combined company.
  • Woburn, Massachusetts-based Comera Life, is developing new biologic medicines to improve safety and convenience for patients, switching from intravenous to subcutaneous injections.
  • Comera applies its formulation platform, SQore, to develop a portfolio of proprietary subcutaneous (SQ) therapeutics. 
  • Comera will also continue collaborating with pharmaceutical and biotechnology companies, applying its SQore platform to partners’ biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
  • The merger will close in Q2 FY22.
  • Price Action: OTRA shares are trading 0.13% higher at $10.17 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CareFinancingOfferingsIPOsGeneralBriefsSPAC
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!